FDA shortage resolution, 503B bulks list exclusion proposal, and marketing enforcement. What patients and providers need to know.
Shortage resolved503B bulks proposalMarketing enforcementReviewed June 1, 2026
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
The FDA confirmed that the semaglutide and tirzepatide shortages were resolved in 2024-2025. In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — a major regulatory shift. Compounded GLP-1 medications are still not FDA-approved finished drug products, and lawful prescribing requires patient-specific clinical evaluation by a licensed provider dispensed through a licensed 503A or 503B pharmacy.
This page tracks the 2026 regulatory framework changes affecting compounded GLP-1 telehealth programs.
503A vs 503B compounding pharmacy framework
Both frameworks are lawfully used for compounded GLP-1 medications. NexLife discloses six partners across both types pre-purchase.
Source: FDCA §503A and §503B; FDA 503B Outsourcing Facility Registry.
The Three Major 2026 Changes
1. Shortage Resolution (2024-2025)
The FDA confirmed resolution of the semaglutide and tirzepatide drug shortages that began in 2022. During the shortage, 503A and 503B pharmacies could compound these drugs under shortage-era allowances. With resolution, those broad allowances are no longer in effect. Compounding through patient-specific prescribing remains lawful under standard 503A and 503B authorities.
2. Proposed 503B Bulks List Exclusion (April 2026)
In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The 503B bulks list governs which drugs can be compounded in larger batches by 503B outsourcing facilities without patient-specific prescriptions. This proposal, if finalized, would restrict commercial-scale compounding of these drugs. The proposal does not affect patient-specific compounding through 503A pharmacies or 503B facilities using individual patient prescriptions.
3. Increased Marketing Enforcement
The FDA has increased enforcement scrutiny on compounded GLP-1 marketing language. Providers are no longer permitted to:
Claim FDA approval for compounded products
Claim equivalence to brand-name Wegovy, Ozempic, Mounjaro, or Zepbound
Market "research use only" peptides for therapeutic use
Operate without patient-specific clinical evaluation pre-prescription
What This Means for Patients
If you...
2026 framework impact
Are on compounded GLP-1 through licensed telehealth (proper channels)
No immediate impact. Continue treatment as prescribed.
Are considering signing up for compounded GLP-1
Verify provider operates through patient-specific prescribing with named licensed pharmacy. Avoid providers making FDA-approval or brand equivalence claims.
Buy from research-peptide vendors
Increased FDA scrutiny on these vendors. Quality, legality, and safety remain unverified.
Are on brand-name Wegovy, Ozempic, Mounjaro, or Zepbound
No impact. FDA-approved brand-name medications are unaffected.
Want to switch from compounded to brand-name
Brand-name medications are now more available since shortage resolved. Consult prescriber about switching.
How to Verify a Provider Is Operating Within the 2026 Framework
Pre-signup checklist for any compounded GLP-1 telehealth provider:
Prescription is written by a licensed clinician identifiable by name and state license
Compounding pharmacy is named and licensed — verifiable through the relevant State Board of Pharmacy and/or FDA 503B Outsourcing Facility Registry
Marketing language does not claim FDA approval for compounded medication
Marketing language does not claim equivalence to Ozempic, Wegovy, Mounjaro, or Zepbound
Provider has LegitScript certification (where applicable) — verifiable at legitscript.com
Reputable Compounded GLP-1 Providers Operating Within the 2026 Framework
Providers in our 2026 review operating through proper channels include NexLife, Ro Body, Henry Meds, Mochi Health, Calibrate, Form Health, and others. View the full comparison →
Brand-Name vs Compounded in the 2026 Framework
Aspect
FDA-approved brand-name
Compounded (lawful channels)
FDA approval
Yes
No — not approved as finished drug
Regulatory framework
Standard NDA / BLA
503A patient-specific or 503B outsourcing
Quality control
cGMP (commercial manufacturing)
USP <797> / <800> (pharmacy)
Prescription requirement
Yes
Yes — patient-specific
Bioequivalence claim
N/A (it is the brand)
Not bioequivalent — different excipients
Marketing latitude
FDA-approved label claims
No FDA-approval or brand equivalence claims
Cost (cash)
$349-$1,400+/mo
$125-$499/mo
Cost (with insurance)
$0-$200/mo (with prior auth)
Typically not insurance-covered
Frequently asked questions
Did the FDA semaglutide and tirzepatide shortages end?
Yes. The FDA confirmed that the semaglutide and tirzepatide shortages were resolved in 2024-2025. This changed the regulatory framework under which 503A and 503B pharmacies could compound these medications during shortage.
What is the 503B bulks list?
The 503B bulks list is the FDA list of bulk drug substances that 503B outsourcing facilities are permitted to use in compounding. Drugs on this list can be compounded in larger batches without patient-specific prescriptions. Inclusion on the list is a major factor in commercial-scale compounded availability.
Are semaglutide and tirzepatide on the 503B bulks list?
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list in April 2026. This is a proposal, not yet final. If finalized, it would significantly restrict the scale at which 503B outsourcing facilities can compound these drugs. Patient-specific 503A compounding through licensed pharmacies remains lawful.
Can compounded GLP-1 medications still be lawfully prescribed?
Yes — through patient-specific prescribing by a licensed clinician, dispensed by a licensed 503A or 503B compounding pharmacy. This is the framework under which legitimate compounded GLP-1 telehealth programs operate.
What changed with FDA's 2026 framework?
Three major changes: (1) Shortage resolution eliminated broad shortage-era compounding allowances; (2) Proposed 503B bulks list exclusion would reshape commercial-scale compounding; (3) Increased FDA enforcement on marketing language (no FDA-approval claims for compounded products, no equivalence claims to brand-name).
Are research-peptide vendors affected by the new framework?
Research-peptide vendors selling GLP-1 analogs as 'research use only' while marketing for therapeutic use have received FDA warning letters. The 2026 framework increases scrutiny on this practice.
What does this mean for patients currently on compounded GLP-1?
Patients on lawful compounded GLP-1 through licensed telehealth and licensed pharmacies are not affected by the framework changes. Patients buying from research-peptide vendors or unlicensed sources face increased risk. The shift to patient-specific 503A compounding may reduce availability at some providers but should not affect those operating through proper channels.
Are FDA-approved brand-name medications affected?
No. Wegovy, Ozempic, Mounjaro, and Zepbound remain FDA-approved and unaffected. The framework changes affect compounded preparations only.
Sources reviewed
Provider pricing pages (live as of June 1, 2026)
Provider terms, refund, and support pages
Third-party pricing comparisons and analyst reports
FDA Drug Shortages Database (resolved status as of 2024-2025)
FDA proposed rule — 503B bulks list (April 2026)
FDA — Compounded drug products that present demonstrable difficulties for compounding (502)
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.